{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32.6","upperLimit":"78.5","value":"55.56"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. 4-year DFS will be estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with Philadelphia chromosome (Ph)-like B-ALL and a predicted TKI-sensitive mutation treated with dasatinib plus MBFM-IMHDM","id":"OG000","title":"Non-DS Ph-like Pred TKI Sensitive Kinase Dasatinib Arm"}],"paramType":"NUMBER","populationDescription":"Patients with Ph-like B-ALL and a predicted tyrosine kinase inhibitor (TKI)-sensitive mutation treated with dasatinib plus MBFM-IMHDM","reportingStatus":"POSTED","timeFrame":"Up to 4 years","title":"DFS for Children and Young Adults With Ph-like B-ALL and a Predicted Tyrosine Kinase Inhibitor (TKI)-Sensitive Mutation Treated With Dasatinib Plus MBFM-IMHDM","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}